Bristol Myers Squibb Sells Convatec A Strategic Shift In Focus to Biopharmaceuticals

Date: May 1, 2008
Pages: 35
Price:
US$ 500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B7A85DE0B8EEN
Leaflet:

Download PDF Leaflet

Bristol Myers Squibb Sells Convatec A Strategic Shift In Focus to Biopharmaceuticals
GlobalData viewpoints are an essential source of high quality information on all key events in the medical equipment industry. GlobalData viewpoints are typically our opinion on the key events, strategic rationale and its impact on the future outlook of the medical equipment sectors. GlobalData viewpoints cover financial deals and their impact on the competitive landscape, impact of product approvals on existing market segments, emerging technologies and products in develoopment, reimbursement policies and impact on procedure numbers, government policies and reforms to make devices safer and effective through regulatory changes.

Scope

• Viewpoints are a source of real-time and frequent updates on key events in the medical equipment sectors and provide insights on market size (historic and forecast), procedure numbers, pricing trends and competitive landscape
• Viewpoints provide in depth analysis of market drivers, restraints and trends impacting the future of the sectors and sub-sectors
• Viewpoints are analytical alerts that provide information on emerging technologies and products in development by sector with commentaries on clinical trial outcomes and commercialization plans

Reasons to buy

• Be abreast of key events in the medical device industry
• Make informed decisions by understanding the rationale behind key events
• Align your market strategies with the events which can impact your business
• Develop proactive marketing strategies and business plans through real-time updates of pipeline products, technologies and financial deals

1 TABLE OF CONTENTS


1.1 LIST OF TABLES


1.2 LIST OF FIGURES


2 GLOBALDATA VIEWPOINT

2.1 Summary

3 BRISTOL MYERS SQUIBB SELLS CONVATEC: A STRATEGIC SHIFT IN FOCUS TO BIOPHARMACEUTICALS

3.1 Wound Care Management Market Overview
3.2 Bristol-Myers Squibb Outlook
  3.2.1 Focus on Biopharmaceuticals
3.3 Avista and Nordic Capital’s Outlook
  3.3.1 Lucrative Expansion Option
  3.3.2 Growth Strategies for Avista
  3.3.3 Growth Strategies for Nordic
3.4 Convatec’s Outlook
3.5 Deals in the Wound care Management Market 2008
  3.5.1 Acquisition
  3.5.2 Private Equity
  3.5.3 Venture Financing
  3.5.4 IPO
  3.5.5 Debt Offerings
  3.5.6 Partnership
3.6 Outlook and Implications
3.7 Related News
  3.7.1 ConvaTec Introduces VERSIVA XC Gelling Foam Dressings To US
  3.7.2 ConvaTec Upgrades Flexi-Seal Fecal Management System To Increase Ease Of Use
  3.7.3 Vivolution Acquires Patent From BMS
  3.7.4 Avista Capital Partners Acquires Bristol-Myers Squibb Medical Imaging From Bristol-Myers Squibb

4 APPENDIX

4.1 Methodology
  4.1.1 Coverage
  4.1.2 Secondary Research
  4.1.3 Primary Research
  4.1.4 Models
  4.1.5 Forecasts
  4.1.6 Expert Panel Validation
4.2 Contact Us
4.3 About GlobalData
4.4 Disclaimer

1.1 LIST OF TABLES

Table 1: Wound Care Management Market Deals, by Type, 2008

1.2 LIST OF FIGURES

Figure 1: Wound Care Management Market Revenues By Category, 2004-2012, ($ m)
Figure 2: Convatec Sales, 2005-2007, ($ m)
Figure 3: Convatec Medical Equipment Revenue Segmentation, 2006
Figure 4: GlobalData Methodology

Ask Your Question

Bristol Myers Squibb Sells Convatec A Strategic Shift In Focus to Biopharmaceuticals
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: